C. difficile

CDI is difficult to contain in health care settings because some patients are unknowing carriers of the toxigenic strains of the infection.

Antibiotic prescribing at hospital discharge is a component of pharmacist-led antimicrobial stewardship programs that is often overlooked.

Clostridioides difficile infection was found to increase the risk of all-cause and cause-specific mortality in a recent study.

The data could inform how non–steroidal anti-inflammatory drug-mediated mitochondrial uncoupling could affect other diseases.

For many patients with C diff, the experience of medical gaslighting is a common one because many health care providers lack education and familiarity with the disease.

Pharmacist-led discharge stewardship initiatives have shown promising results.

Data show these cases pose some of the most significant threats to patients and health systems.

MicroRNA has shown the potential to more effectively and accurately identify C. difficile infections and manage it after diagnosis.

Fecal microbiota transplantation is a process that restores bacterial diversity in the gut microbiome after standard-of-care antimicrobial therapy.

Clostridioides difficile infection can be difficult to treat, but increasing disease awareness can improve screening and treatment outcomes.

As one of the most trusted health care professionals, pharmacists play a vital role in debunking medication myths by providing patients with accurate information to make positive decisions regarding their health.

Investigators identified potential ways to inhibit the HpdBCA decarboxylase, which can reduce the production of p-cresol and make CDI more susceptible to bacteria in the gut microbiome.

Antibiotics that were found to be most commonly associated with clostridium difficile infection are piperacillin/tazobactam, meropenem, vancomycin, ciprofloxacin, ceftriaxone, and levofloxacin, according to a recent study.

The novel antibiotic combines aztreonam, a monobactam β-lactam, with avibactam, a broad-spectrum β-lactamase inhibitor.

Patient education and counseling play a critical role in preventing C. difficile recurrence, and pharmacists are uniquely positioned to provide treatment recommendations, educate patients and health care providers, optimize transitions of care, and reduce the risk of recurrent CDI.

Joseph Reilly, BS, PharmD, BCGP, reviews the positive economic impact of use of live-jslm for treatment of CDI in a hospital setting.

Experts comment on the measures that need to be taken to prevent or control the spread of CDI in the healthcare setting.

Randomized clinical trials still showed that microbiota restoration is significantly more effective than antibiotics for recurrent Clostridioides difficile infection.

Rebyota is a live biotherapeutic product that is unfamiliar to many pharmacists and other health care providers with different steps in the eventual administration process.

Candace Cotto, RN, and Andrew Skinner, MD, discuss barriers to use of FMTs in managing CDI, highlighting clinician and patient education.

Experts comment on insurance coverage as a factor for the broader use of FMTs for the management of CDI.

In Greece, the stark increase in Clostridioides difficile (C. diff) incidence cannot be explained by a rise of antimicrobial use during the pandemic.

Candace Cotto, RN, reviews the process of incorporating fecal microbiota, live-jslm treatment into clinical practice, what patients can expect, and the room sanitation process after the procedure.

Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.

The results of a recent study suggest that a testing policy change for C. difficile could decrease the risk of additional infections and the corresponding economic burden on the hospital.

Supportive nurse managers and supervisors as well as nurses’ involvement in organizational governance may help lower hospital-onset Clostridioides difficile infection in acute care hospitals.

Joseph Reilly, BS, PharmD, BCGP, and Andrew Skinner, MD, discuss the potential benefits of using live-jslm early on to treat CDI, as well as the implications of this new treatment.

Joseph Reilly, BS, PharmD, BCGP, provides an overview of a new FDA-approved FMT therapy, live-jslm for the treatment of CDI.

Treatment-emergent adverse events were reported in a similar proportion of participants with recurrent Clostridioides difficile infection, both with and without immunocompromising conditions.

Candace Cotto, RN, and Andrew Skinner, MD, discuss the challenges of traditional fecal microbiota transplantation (FMT) in treatment of CDI.